{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}],"title":"Progressive disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Percentage of patients who have received at least one dose of pembrolizumab and have responded (and have completed imaging requirements). Best overall response is defined as the best overall visit response in the following order: CR, PR, SD, PD, or UE as measured by RECIST 1.1","groups":[{"description":"* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy\n* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab","id":"OG000","title":"Ovarian Cancer (OvC)"},{"description":"One subject enrolled but discontinued before efficacy can be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety.","id":"OG001","title":"Colorectal Cancer (CRC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who have received at least one dose of pembrolizumab (mITT population). Patients only enrolled in the Ovarian Cancer (OvC) arm. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy can be assessed. The other arms/groups were removed from this study.","reportingStatus":"POSTED","timeFrame":"33 months","title":"Overall Response Rate (ORR) - Best Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}